SDGCF:OTC-Sundrug Co.,Ltd (USD)

COMMON STOCK | Pharmaceutical Retailers | OTC

Last Closing Price

USD 32.47

Change

0.00 (0.00)%

Market Cap

USD 3.81B

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Sundrug Co.,Ltd. operates and manages drug stores and dispensing pharmacies in Japan. It also operates discount stores that offers food, cosmetics, home appliances, clothing, car supplies, sports and goods, alcoholic beverages, and pharmaceutical products, as well as fresh food, kerosene, etc. The company was founded in 1957 and is headquartered in Fuchu, Japan.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-20 )

Largest Industry Peers for Pharmaceutical Retailers

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALBHF Alibaba Health Information Tec..

N/A

USD29.27B 542.50 70.16
RADLY Raia Drogasil S.A

N/A

USD8.89B 84.14 4.34
CLCGY Clicks Group Limited

N/A

USD4.83B 34.98 1.11
ZRSEF Zur Rose Group AG

N/A

USD4.09B N/A N/A
FFLWF Fire & Flower Holdings Corp

N/A

USD0.29B N/A 11.91
DRVD Driven Deliveries, Inc

N/A

USD0.06B N/A N/A
RXMD Progressive Care, Inc

N/A

USD0.03B N/A 17.28
HADV Health Advance Inc

N/A

USD0.01B N/A N/A
HEWA HealthWarehouse.com, Inc

N/A

USD8.78M 56.67 N/A
RLLVF Relevium Technologies Inc

N/A

USD2.07M N/A N/A

ETFs Containing SDGCF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Pharmaceutical Retailers)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.54% 25% F 15% F
Dividend Return 89.96% 100% A+ 98% A+
Total Return 73.42% 63% D 76% C
Trailing 12 Months  
Capital Gain 9.11% 33% F 28% F
Dividend Return 118.69% 100% A+ 98% A+
Total Return 127.79% 60% D- 73% C
Trailing 5 Years  
Capital Gain -59.15% 30% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.15% 30% F 16% F
Average Annual (5 Year Horizon)  
Capital Gain -7.62% 12% F 16% F
Dividend Return 34.98% 100% A+ 96% A
Total Return 27.36% 35% F 63% D
Risk Return Profile  
Volatility (Standard Deviation) 71.92% 71% C- 40% F
Risk Adjusted Return 38.04% 65% D 64% D
Market Capitalization 3.81B 76% C 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Pharmaceutical Retailers)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 16.60 71% C- 48% F
Price/Book Ratio 2.09 78% C+ 47% F
Price / Cash Flow Ratio 0.12 50% F 47% F
EV/EBITDA 0.08 86% B 82% B-
Management Effectiveness  
Return on Equity 12.92% 90% A- 79% C+
Return on Invested Capital -12.70% 40% F 24% F
Return on Assets 7.88% 92% A- 91% A-
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.49 47% F 67% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.